Copd Exacerbation

For patients with COPD who experienced an exacerbation in the last 12 months, add-on azithromycin therapy was deemed cost-effective, according to results published in Annals of the American Thoracic Society.

Respiratory-specific quality of life and exacerbation odds in former smokers with COPD may improve with elevated omega-3 levels, according to research published in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation.

The FDA is expected to make a decision on ensifentrine to treat patients with COPD by June 26.

SAN DIEGO — With dupilumab vs. placebo, adults with moderate to severe COPD and type 2 inflammation experienced fewer exacerbations, according to research presented at the American Thoracic Society International Conference.

SAN DIEGO — After 1 year of biologic therapy, patients with COPD and Th2 inflammation experienced fewer exacerbations and hospitalizations, according to research presented at the American Thoracic Society International Conference.

SAN DIEGO — Among patients with moderate to very severe COPD receiving tezepelumab vs. placebo, the annualized rate of exacerbations dropped by 17%, according to research presented at the American Thoracic Society International Conference.

SAN DIEGO — Bisoprolol treatment yielded a similar yearly rate of COPD exacerbations that require oral corticosteroids and/or antibiotics to placebo, according to research presented at the American Thoracic Society International Conference.

SAN DIEGO — Patients with COPD treated with targeted lung denervation along with optimal COPD therapy experienced fewer exacerbations over 2 years, according to research presented at the American Thoracic Society International Conference.

Based off of the Rome severity classification for COPD exacerbations, more hospitalized patients with severe vs. mild exacerbation received mechanical ventilation and died over 3 years, according to results published in CHEST.